The TDP-43 RNA Granule Pathway describes the molecular cascade from normal TDP-43 nuclear-cytoplasmic shuttling through stress granule dynamics to pathological TDP-43 aggregation in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This pathway represents a critical link between physiological RNA metabolism and neurodegeneration, with stress granules serving as both protective intermediates and pathological precursors.
This mechanism page comprehensively covers: (1) TDP-43 nuclear-cytoplasmic shuttling under normal and stress conditions, (2) stress granule formation and dynamics, (3) the liquid-liquid phase separation (LLPS) transitions that drive pathology, (4) autophagy clearance mechanisms, and (5) therapeutic targeting strategies.
TAR DNA-binding protein 43 (TDP-43), encoded by the TARDBP gene on chromosome 1p36.22, is a 414-amino acid RNA-binding protein that normally localizes predominantly to the nucleus but continuously shuttles between nuclear and cytoplasmic compartments[1]. This shuttling is essential for its functions in both compartments:
Nuclear Functions:
Cytoplasmic Functions:
The nucleocytoplasmic shuttling is mediated by a canonical nuclear localization signal (NLS) in the N-terminal domain (residues 82-98) and active transport via importin-α/β1 heterodimers[1:1]. Under normal conditions, TDP-43 rapidly cycles between compartments with a nuclear residence time of approximately 30-60 minutes.
Under cellular stress conditions (oxidative stress, heat shock, osmotic stress, ER stress), TDP-43 redistribution to the cytoplasm is dramatically enhanced[2]. This redistribution follows a well-characterized sequence:
This stress-induced redistribution is typically reversible upon stress resolution, with TDP-43 returning to the nucleus once homeostasis is restored.
In ALS and FTD, the normal shuttling cycle is disrupted at multiple points[3]:
Mechanism 1: Enhanced Cytoplasmic Retention
Mechanism 2: Impaired Nuclear Re-import
Mechanism 3: Stress Granule Persistence
Stress granules (SGs) are cytoplasmic membrane-less organelles that form dynamically in response to cellular stress[4]. They serve as temporary repositories for:
TDP-43 is recruited to stress granules under stress conditions through multiple mechanisms[3:1]:
The dynamics of TDP-43 in SGs include:
The critical transition from dynamic stress granules to pathological TDP-43 inclusions involves several stages[5]:
Stage 1: Formation of TDP-43-Positive SGs
Stage 2: Intra-Condensate Demixing
Stage 3: Gelation/Solidification
Stage 4: Inclusion Formation
Stress granule resolution occurs through multiple pathways[6]:
1. Autophagy-dependent clearance (SGRNA)
2. Proteasome-dependent clearance
3. Ribophagy
In ALS and FTD, multiple clearance mechanisms fail[7]:
p62 dysfunction:
Autophagy adaptor defects:
Sequestration vs. degradation:
Enhanced clearance represents a major therapeutic strategy:
| Target | Approach | Status |
|---|---|---|
| Autophagy induction | Rapamycin, trehalose | Preclinical |
| TFEB activation | Gene therapy, small molecules | Preclinical |
| p62 modulation | Enhancing recruitment | Research |
| Lysosomal enhancement | Acidification agents | Research |
The autophagy-lysosome system provides the primary clearance route for TDP-43 aggregates[8]. Key pathways include:
1. p62/SQSTM1-mediated selective autophagy
2. OPTN-mediated autophagy
3. NDP52/CALCOCO2-mediated autophagy
Multiple strategies aim to enhance TDP-43 clearance:
Autophagy enhancement:
Selective autophagy targeting:
Lysosomal function:
The cytoplasmic aggregation of TDP-43 leads to loss of its essential nuclear functions[9]:
The nuclear loss appears to be an early and critical event, potentially preceding cytoplasmic aggregation detectable by histology.
Cytoplasmic TDP-43 aggregates may exert toxic effects:
Emerging evidence suggests TDP-43 aggregates can template conversion of normal TDP-43[10]:
TDP-43 pathology impacts mitochondrial function:
Mitochondrial protectants represent an adjunctive strategy:
| Target | Strategy | Development Stage |
|---|---|---|
| TDP-43 expression | ASO silencing | Phase 1-2 |
| Aggregation | Small molecule inhibitors | Preclinical |
| SG dynamics | Phase separation modulators | Preclinical |
| Autophagy | Clearance enhancers | Preclinical |
| Nuclear import | Importin modulators | Research |
| Propagation | Seeding blockers | Research |
Ayala YM, Zago P, D'Ambrogio A, et al. TDP-43 regulates its own nuclear-cytoplasmic shuttling via importin-alpha. EMBO J. 2008. ↩︎ ↩︎
Winton MJ, Igaz LM, Wong MM, et al. Distinguishing between nuclear and cytoplasmic TDP-43 inclusions. J Neurosci. 2008. ↩︎
Dormann D, Rodde R, Katze C, et al. ALS-associated mutations in TDP-43 increase propensity of cytoplasmic TDP-43 to form stress granule-like assemblies. EMBO J. 2010. ↩︎ ↩︎
Wolozin B. Regulated stress granule formation in ALS. Nat Neurosci. 2012. ↩︎
Yan X, et al. Intra-condensate demixing of TDP-43 inside stress granules generates pathological aggregates. Cell. 2025. ↩︎
Li YR, King OD, Shorter J, et al. Stress granules as crucial intermediates in RNA granule autophagy. Autophagy. 2013. ↩︎
Filimonenko M, Efeyan A, Selector S, et al. p62/SQSTM1 forms ribonucleoprotein inclusions that sequester cargo destined for lysosomal degradation. J Cell Biol. 2010. ↩︎
Bickel K, Gendron T, Di T, et al. Role of stress granule regulation in ALS and FTD. Nat Rev Neurol. 2020. ↩︎
Ristos N, Petrucelli L. Measures of bodily TDP-43 in ALS. Nat Rev Neurol. 2018. ↩︎
Scialò C, et al. Seeded aggregation of TDP-43 induces its loss of function and reveals early pathological signatures. Neuron. 2025. ↩︎